{
    "raw_text": "Patients with biopsy-proven metastatic carcinoid tumors or other neuroendocrine tumors (Islet cell, Gastrinomas and VIPomas) with at least one measurable lesion (other than bone) that has either not been previously irradiated or if previously irradiated has demonstrated progression since the radiation therapy \nThe patient has no major impairment of renal or hepatic function, as defined by the following laboratory parameters: total bilirubin <1.5 X ULN; AST, ALT<2.5X ULN (<5 X ULN if liver metastases are present) \nPatients on Sandostatin Lar (long acting somatostatin analogue) must be on a stable dose for 30 days prior to study entry and short acting somatostatin analogues must be judged to be on a clinically stable dose by the investigator prior to study entry \nMust have a life expectancy of greater than three (3) months \nKarnofsky Performance Status > 60 \nFemale patients must have a negative serum pregnancy test at screening. (Not applicable to patients with bilateral oophorectomy and/or hysterectomy or to those patients who are postmenopausal.) \n",
    "category": "hierarchical_criterion",
    "parent_Criterion": {
        "raw_text": "Patients with biopsy-proven metastatic carcinoid tumors or other neuroendocrine tumors (Islet cell, Gastrinomas and VIPomas)"
    },
    "child_Criterion": {
        "raw_text": "with at least one measurable lesion (other than bone) that has either not been previously irradiated or if previously irradiated has demonstrated progression since the radiation therapy"
    },
    "additional_information": [
        "The tumors must be biopsy-proven.",
        "The measurable lesion must not be in the bone.",
        "If the lesion was previously irradiated, it must have shown progression since the radiation therapy."
    ]
}